Whether you are a researcher or a clinician, you use data everyday to guide your decision-making—impacting your clinical trials and patients’ lives.
Imagine being able to
Using measurements like body mass index (BMI) that categorize people into broad categories, or even simply describing individuals as having high liver fat and low liver fat often end up grouping individuals with little resemblance to one another in terms of health and disease.
Specific fat distributions have been significantly linked to adverse health outcomes, something that other body composition methods, such as DXA, single-slice CT/MRI, and BMI, fail to accurately describe.
With our MRI-based method for assessing body composition, we can reliably and precisely view and quantify fat distribution within an individual and individual muscles.
It’s not the fat, it’s where it’s at. (National Geographic, January 2019)
Complex diseases, such as neuromuscular disorders, often present differently between people and between disease stages within an individual—making it difficult to know which muscles to evaluate or monitor for each person.
Conventional imaging methods only look at certain body parts, or parts of single muscles, which can create a false idea of what is actually going on inside the body. AMRA looks at the whole-body and at whole muscles—nothing gets missed.
Recent studies highlight a connection between sarcopenia and chronic liver diseases—which can eventually progress to patients needing a liver transplant. Accurately assessing sarcopenia can help predict, diagnose, and monitor a disease, as well as help determine how a patient will respond to transplant.
Unfortunately, current muscle-based sarcopenia definitions fail to detect sarcopenia in many patients, particularly those with obesity, which is overrepresented in NAFLD (non-alcoholic fatty liver disease). Until recently, the skeletal muscle-liver crosstalk and the impact of treatment interventions on skeletal muscle have been largely overlooked in the research for NAFLD treatments.
Listen to our Muscle-Liver Crosstalk webinar, where experts in liver and metabolic diseases, and imaging, discuss the latest research on how to assess and monitor sarcopenia in chronic liver disease. Click the button below.